{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:58:16Z","timestamp":1761058696729},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,6,21]],"date-time":"2007-06-21T00:00:00Z","timestamp":1182384000000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:p><jats:bold>Background:\u2003<\/jats:bold> The paclitaxel, ifosfamide, and cisplatin regimen has been used to treat metastatic testicular cancer with successful results. We investigated the usefulness of a paclitaxel, ifosfamide, and nedaplatin (TIN) regimen as salvage therapy for patients with advanced testicular germ cell tumors (GCTs).<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> Eight patients with advanced GCTs were treated with TIN. The treatment was performed as salvage therapy for cases refractory to therapies, such as bleomycin, etoposide and cisplatin, and irinotecan with nedaplatin. The TIN regimen consisted of paclitaxel (200\u2003mg\/m<jats:sup>2<\/jats:sup>) by 24\u2010h infusion on day 1, followed by ifosfamide (1.2\u2003g\/m<jats:sup>2<\/jats:sup>) infusions over 2\u2003h on days 2\u20136, and nedaplatin (100\u2003mg\/m<jats:sup>2<\/jats:sup>) given over 2\u2003h on day 2.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> Seven out of eight patients achieved a disease\u2010free status after chemotherapy, followed by surgical resection of the residual tumor. Six of the seven patients have continued to show no evidence of disease after salvage therapy, with a median follow\u2010up period of 27\u2003months, but one patient developed a \u2018growing teratoma syndrome\u2019 in the mediastinum 31\u2003months after TIN chemotherapy. All patients developed grade 4 leukocytopenia. However, it could be managed by using granulocyte colony\u2010stimulating factor. Only one patient developed grade 2 sensory neuropathy and no patient developed nephrotoxicity.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> The TIN regimen was efficacious and well\u2010tolerated as salvage chemotherapy for Japanese patients with advanced GCTs.<\/jats:p>","DOI":"10.1111\/j.1442-2042.2006.01702.x","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T04:41:00Z","timestamp":1182487260000},"page":"527-531","source":"Crossref","is-referenced-by-count":13,"title":["Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors"],"prefix":"10.1111","volume":"14","author":[{"given":"Norio","family":"Nonomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daizo","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneharu","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.072067999"},{"key":"e_1_2_5_3_2","first-page":"2630","article-title":"Testicular cancer: an oncological success story","volume":"3","author":"Einhorn EH","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1193::AID-CNCR28>3.0.CO;2-W"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2559"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2500"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi228"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2413"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyg029"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"e_1_2_5_11_2","volume-title":"General Rules for Clinical and Pathological Studies on Testicular Tumors","author":"Japanese Urological Association\/The Japanese Society of Pathology.","year":"2005"},{"key":"e_1_2_5_12_2","unstructured":"National Cancer Institute.National Cancer Institute Common Toxicity Criteria (Version 3.0).2003. [Cited 3 10 2005.] Available from URL:http:\/\/ctep.cancer.gov\/reporting\/ctc.html)."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01194278"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2277"},{"key":"e_1_2_5_15_2","first-page":"12","article-title":"Paclitaxel in germ cell cancer","volume":"22","author":"Motzer RJ","year":"1995","journal-title":"Semin. Oncol."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1173"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011628900089"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685546"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02994087"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00219-0"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10918"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00103-2"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-2042.2006.01702.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-2042.2006.01702.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:27:05Z","timestamp":1697315225000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-2042.2006.01702.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1111\/j.1442-2042.2006.01702.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-2042.2006.01702.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}